CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis
Introduction
The treatment landscape for acute myeloid leukemia (AML) has shifted dramatically from a morphology-based approach to one governed by molecular genetics. CPX-351, a liposomal formulation of cytarabine and daunorubicin in a fixed 5:1 molar ratio, was initially approved based on its superior overall survival (OS) compared to the standard 7+3 regimen in older patients with previously untreated, high-risk AML. However, the original trial (NCT01696084) utilized clinical and morphological definitions that have since been superseded by the World Health Organization (WHO) 5th Edition and International Consensus Classification (ICC). A critical question remained: Does the survival benefit of CPX-351 apply broadly to high-risk patients, or is it restricted to specific molecularly defined subgroups?
Background and Clinical Context
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.